Biogen Idec Finalizes Phase III Plans For Aducanumab In Alzheimer’s
Executive Summary
Though performance of a middle 6 mg/kg dose cohort just disappointed investors in the Phase Ib PRIME trial, company is confident with using this regimen in two large Phase III studies.